Entry Point Capital, LLC Intellia Therapeutics, Inc. Transaction History

Entry Point Capital, LLC

  • $171 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$20.02 - $27.22 $76,076 - $103,436
-3,800 Reduced 92.19%
322 $7.21 Million
Q1 2024

May 14, 2024
BUY
$23.82 - $32.8 $37,230 - $51,266
1,563 Added 61.08%
4,122 $113 Million
Q4 2023

Feb 14, 2024
BUY
$23.16 - $32.34 $59,266 - $82,758
2,559 New
2,559 $78 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email